A comparison of two GM-CSF schedules to counteract the granulo-monocytopenia of carboplatin-etoposide chemotherapy

S. Tafuto, G. Abate, P. D'Andrea, I. Silvestri, P. Marcelin, C. Volta, A. Monteverde, S. Colombi, S. Andorno, M. Aglietta

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

In order to obtain the beneficial effects from granulocyte-macrophage colony-stimulating factor (GM-CSF) on granulo-monocyte recovery with the minimum dose and toxicity, we compared the effect of two different GM-CSF schedules (5 μg/kg/day subcutaneously, days 5 to > 18 versus days 12 to > 18 on the cytopenias which follow cytostatic treatment with carboplatin (400 mg/m2 intravenous (i.v.) day 1) and etoposide (100 mg/m2 i.v. days 1 to > 3). 13 patients entered the study for a total of 36 evaluable cycles. The cytostatic treatment produced a neutropenia that persisted for up to day 22 (absolute neutrophil count (ANC) <1000/μl in 25% and ANC <2000 in 50% of control cycles). Early GM-CSF administration markedly increased the leucocyte nadir and produced two waves of leucocytosis: an early one, linked to marrow reserve release and presumably of no value to the patients; and a delayed one, due to marrow precursor and progenitor cell proliferation, in which the granulomonocytosis was associated with a marked eosinophilia. The delayed GM-CSF administration markedly increased the leucocyte nadir and accelerated granulo-monocyte recovery (with an only modest eosinophilia), so that chemotherapy could be repeated every 21 days in all the patients.

Original languageEnglish
Pages (from-to)46-49
Number of pages4
JournalEuropean Journal of Cancer
Volume31
Issue number1
DOIs
Publication statusPublished - 1995

Fingerprint

Carboplatin
Etoposide
Granulocyte-Macrophage Colony-Stimulating Factor
Appointments and Schedules
Drug Therapy
Eosinophilia
Cytostatic Agents
Monocytes
Neutrophils
Leukocytes
Bone Marrow
Leukocytosis
Neutropenia
Stem Cells
Cell Proliferation
Therapeutics

Keywords

  • cancer chemotherapy
  • carboplatin
  • dose intensity
  • etoposide
  • GM-CSF
  • neutropenia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology

Cite this

A comparison of two GM-CSF schedules to counteract the granulo-monocytopenia of carboplatin-etoposide chemotherapy. / Tafuto, S.; Abate, G.; D'Andrea, P.; Silvestri, I.; Marcelin, P.; Volta, C.; Monteverde, A.; Colombi, S.; Andorno, S.; Aglietta, M.

In: European Journal of Cancer, Vol. 31, No. 1, 1995, p. 46-49.

Research output: Contribution to journalArticle

Tafuto, S, Abate, G, D'Andrea, P, Silvestri, I, Marcelin, P, Volta, C, Monteverde, A, Colombi, S, Andorno, S & Aglietta, M 1995, 'A comparison of two GM-CSF schedules to counteract the granulo-monocytopenia of carboplatin-etoposide chemotherapy', European Journal of Cancer, vol. 31, no. 1, pp. 46-49. https://doi.org/10.1016/0959-8049(94)00270-F
Tafuto, S. ; Abate, G. ; D'Andrea, P. ; Silvestri, I. ; Marcelin, P. ; Volta, C. ; Monteverde, A. ; Colombi, S. ; Andorno, S. ; Aglietta, M. / A comparison of two GM-CSF schedules to counteract the granulo-monocytopenia of carboplatin-etoposide chemotherapy. In: European Journal of Cancer. 1995 ; Vol. 31, No. 1. pp. 46-49.
@article{dc280e665fd547f5b320e0d5da088d39,
title = "A comparison of two GM-CSF schedules to counteract the granulo-monocytopenia of carboplatin-etoposide chemotherapy",
abstract = "In order to obtain the beneficial effects from granulocyte-macrophage colony-stimulating factor (GM-CSF) on granulo-monocyte recovery with the minimum dose and toxicity, we compared the effect of two different GM-CSF schedules (5 μg/kg/day subcutaneously, days 5 to > 18 versus days 12 to > 18 on the cytopenias which follow cytostatic treatment with carboplatin (400 mg/m2 intravenous (i.v.) day 1) and etoposide (100 mg/m2 i.v. days 1 to > 3). 13 patients entered the study for a total of 36 evaluable cycles. The cytostatic treatment produced a neutropenia that persisted for up to day 22 (absolute neutrophil count (ANC) <1000/μl in 25{\%} and ANC <2000 in 50{\%} of control cycles). Early GM-CSF administration markedly increased the leucocyte nadir and produced two waves of leucocytosis: an early one, linked to marrow reserve release and presumably of no value to the patients; and a delayed one, due to marrow precursor and progenitor cell proliferation, in which the granulomonocytosis was associated with a marked eosinophilia. The delayed GM-CSF administration markedly increased the leucocyte nadir and accelerated granulo-monocyte recovery (with an only modest eosinophilia), so that chemotherapy could be repeated every 21 days in all the patients.",
keywords = "cancer chemotherapy, carboplatin, dose intensity, etoposide, GM-CSF, neutropenia",
author = "S. Tafuto and G. Abate and P. D'Andrea and I. Silvestri and P. Marcelin and C. Volta and A. Monteverde and S. Colombi and S. Andorno and M. Aglietta",
year = "1995",
doi = "10.1016/0959-8049(94)00270-F",
language = "English",
volume = "31",
pages = "46--49",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "1",

}

TY - JOUR

T1 - A comparison of two GM-CSF schedules to counteract the granulo-monocytopenia of carboplatin-etoposide chemotherapy

AU - Tafuto, S.

AU - Abate, G.

AU - D'Andrea, P.

AU - Silvestri, I.

AU - Marcelin, P.

AU - Volta, C.

AU - Monteverde, A.

AU - Colombi, S.

AU - Andorno, S.

AU - Aglietta, M.

PY - 1995

Y1 - 1995

N2 - In order to obtain the beneficial effects from granulocyte-macrophage colony-stimulating factor (GM-CSF) on granulo-monocyte recovery with the minimum dose and toxicity, we compared the effect of two different GM-CSF schedules (5 μg/kg/day subcutaneously, days 5 to > 18 versus days 12 to > 18 on the cytopenias which follow cytostatic treatment with carboplatin (400 mg/m2 intravenous (i.v.) day 1) and etoposide (100 mg/m2 i.v. days 1 to > 3). 13 patients entered the study for a total of 36 evaluable cycles. The cytostatic treatment produced a neutropenia that persisted for up to day 22 (absolute neutrophil count (ANC) <1000/μl in 25% and ANC <2000 in 50% of control cycles). Early GM-CSF administration markedly increased the leucocyte nadir and produced two waves of leucocytosis: an early one, linked to marrow reserve release and presumably of no value to the patients; and a delayed one, due to marrow precursor and progenitor cell proliferation, in which the granulomonocytosis was associated with a marked eosinophilia. The delayed GM-CSF administration markedly increased the leucocyte nadir and accelerated granulo-monocyte recovery (with an only modest eosinophilia), so that chemotherapy could be repeated every 21 days in all the patients.

AB - In order to obtain the beneficial effects from granulocyte-macrophage colony-stimulating factor (GM-CSF) on granulo-monocyte recovery with the minimum dose and toxicity, we compared the effect of two different GM-CSF schedules (5 μg/kg/day subcutaneously, days 5 to > 18 versus days 12 to > 18 on the cytopenias which follow cytostatic treatment with carboplatin (400 mg/m2 intravenous (i.v.) day 1) and etoposide (100 mg/m2 i.v. days 1 to > 3). 13 patients entered the study for a total of 36 evaluable cycles. The cytostatic treatment produced a neutropenia that persisted for up to day 22 (absolute neutrophil count (ANC) <1000/μl in 25% and ANC <2000 in 50% of control cycles). Early GM-CSF administration markedly increased the leucocyte nadir and produced two waves of leucocytosis: an early one, linked to marrow reserve release and presumably of no value to the patients; and a delayed one, due to marrow precursor and progenitor cell proliferation, in which the granulomonocytosis was associated with a marked eosinophilia. The delayed GM-CSF administration markedly increased the leucocyte nadir and accelerated granulo-monocyte recovery (with an only modest eosinophilia), so that chemotherapy could be repeated every 21 days in all the patients.

KW - cancer chemotherapy

KW - carboplatin

KW - dose intensity

KW - etoposide

KW - GM-CSF

KW - neutropenia

UR - http://www.scopus.com/inward/record.url?scp=0028813648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028813648&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(94)00270-F

DO - 10.1016/0959-8049(94)00270-F

M3 - Article

C2 - 7695978

AN - SCOPUS:0028813648

VL - 31

SP - 46

EP - 49

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 1

ER -